Sources: 
NVIDIA is actively democratizing artificial intelligence (AI) in health care, aiming to improve patient outcomes and streamline clinical processes.
The company leverages AI to enhance patient matching, significantly reducing the time required to identify appropriate clinical trial sites, a critical step for pharmaceutical companies.
"AI is poised to augment health care delivery in a way that is beneficial to patients," said Chelsea Sumner, a pharmacist turned NVIDIA advocate.
Sumner emphasizes her role in promoting AI adoption both within NVIDIA and among health care partners, highlighting the importance of interprofessional collaboration.
"We are helping to democratize AI for health care, and my role allows me to be an advocate for our companies both internally and externally to NVIDIA," she explained.
Her background as a pharmacist provides valuable insight into the clinical applications of AI, bridging the gap between technology and patient care.
NVIDIA's efforts reflect a broader trend of integrating AI into health care to enhance efficiency and accessibility, ultimately benefiting patients and pharmaceutical research.
"Leveraging AI and patient match decreases the time it takes to find the right sites for clinical trials, which is a huge process for pharmaceutical companies," Sumner noted.
This democratization of AI tools aims to make cutting-edge clinical technologies more accessible across the health care sector, fostering innovation and improved health outcomes.
Sources: NVIDIA is expanding access to advanced AI tools in health care, enhancing clinical trial efficiency and patient matching. Chelsea Sumner, a pharmacist turned NVIDIA advocate, highlights the company's role in democratizing AI to benefit patients and streamline pharmaceutical processes.
